News: Umeå, 24 May 2021.


On May 26 at 12:00 am Lipum will tell what´s going on in the company and what the future plans look like. Link to the event.

Welcome to meet us!


For further information, please contact: 
Einar Pontén, CEO


Mobile:   +46 70 5783495


About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser iG&W Fondkommission, email:, phone: +46 8 503 000 50.